# Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

> **NCT04648813** · PHASE4 · COMPLETED · sponsor: **University of Saskatchewan** · enrollment: 15 (actual)

## Conditions studied

- Allergic Asthma

## Interventions

- **DRUG:** tiotropium bromide monohydrate (Spiriva Respimat)
- **DRUG:** matching placebo

## Key facts

- **NCT ID:** NCT04648813
- **Lead sponsor:** University of Saskatchewan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-13
- **Primary completion:** 2021-04-20
- **Final completion:** 2021-04-20
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04648813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04648813, "Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04648813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*